NOVEL IMMUNOTHERAPY AGAINST NEURONAL AND BRAIN TUMORS
First Claim
1. A peptide comprising a sequence that is selected from the group of SEQ ID NO:
- 1 to SEQ ID NO;
11 wherein the peptide is capable of inducing T cells cross-reacting with the peptide.
2 Assignments
0 Petitions
Accused Products
Abstract
The present invention relates to peptides, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. The present invention furthermore relates to tumor-associated cytotoxic T cell (CTL) peptide epitopes, alone or in combination with other tumor-associated peptides that serve as active pharmaceutical ingredients of vaccine compositions that stimulate anti-tumor immune responses. The present invention relates to 11 novel peptide sequences and their variants derived from HLA class I and class II molecules of human tumor cells that can be used in vaccine compositions for eliciting anti-tumor immune responses.
-
Citations
40 Claims
-
1. A peptide comprising a sequence that is selected from the group of SEQ ID NO:
- 1 to SEQ ID NO;
11 wherein the peptide is capable of inducing T cells cross-reacting with the peptide. - View Dependent Claims (8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40)
- 1 to SEQ ID NO;
-
2. A peptide comprising an amino acid sequence selected from the group consisting of SEQ ID NO:
- 1 to SEQ ID NO;
11, wherein the peptide maintains the ability to bind to a molecule of the human major histocompatibility complex (MHC) class-I or -II and wherein the peptide is capable of stimulating CD4 or CD8 T cells. - View Dependent Claims (3, 4, 5, 6, 7)
- 1 to SEQ ID NO;
Specification